<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993525</url>
  </required_header>
  <id_info>
    <org_study_id>3003/2009</org_study_id>
    <nct_id>NCT00993525</nct_id>
  </id_info>
  <brief_title>Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)</brief_title>
  <acronym>INIPE</acronym>
  <official_title>INTRAVITREAL RANIBIZUMAB FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (INIPE STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Apoio ao Ensino Pesquisa e Assitência do HCFMRPUSP (FAEPA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the fluorescein angiographic and visual acuity effects of a single intravitreal
      injection of ranibizumab for the management of persistent new vessels associated with
      diabetic retinopathy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>total area of fluorescein leakage from active new vessels</measure>
    <time_frame>baseline, weeks 1,6,12,24,36,48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Best corrected Visual Acuity (BCVA)</measure>
    <time_frame>Baseline, weeks 1,6,12,24,36,48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>central macular thickness</measure>
    <time_frame>baseline, weeks 1,6,12,24,36,48</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Intravitreal anti-VEGF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection of 0.5 mg of ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal injection of ranibizumab</intervention_name>
    <description>0.5 mg at week 0 0.5mg at weeks 12,24,36,48 if fluorescein leakage from active vessels on angiography</description>
    <arm_group_label>Intravitreal anti-VEGF</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  persistent new vessels,defined as fine retinal vessels with dilated buds or tips
             covered with hemorrhage or associated with recurrent vitreous hemorrhage or paucity of
             accompanying fibrous tissue and/or increased in extent compared to previous
             visit,unresponsive to complete panretinal laser photocoagulation performed at least 4
             months prior;

          -  logarithm of minimum angle of resolution (logMAR) best-corrected visual acuity of 0.17
             (Snellen equivalent, 20/30) or worse.

        Exclusion Criteria:

          -  history of vitrectomy in the study eye;

          -  history of thromboembolic event (including myocardial infarction or cerebral vascular
             accident);

          -  major surgery within the prior 6 months or planned within the next 28 days;

          -  uncontrolled hypertension;

          -  known coagulation abnormalities or current use of anticoagulative medication other
             than aspirin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo Jorge, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of São Paulo</affiliation>
  </overall_official>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2009</study_first_submitted>
  <study_first_submitted_qc>October 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2009</study_first_posted>
  <last_update_submitted>October 9, 2009</last_update_submitted>
  <last_update_submitted_qc>October 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Rodrigo Sanches Oliveira</name_title>
    <organization>Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo</organization>
  </responsible_party>
  <keyword>diabetic retinopathy</keyword>
  <keyword>ranibizumab</keyword>
  <keyword>new vessels</keyword>
  <keyword>intravitreal injection</keyword>
  <keyword>Persistent retina new vessels</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

